ELAEXIA Oncosome.HER2
Oncology (HER2-related cancers)
DevelopmentActive
Key Facts
About Therawis
Therawis is a Munich-based oncology diagnostics company leveraging a theranostic model to integrate novel diagnostic tools with targeted therapies. The company has developed the ELAEXIA® platform, utilizing mass spectrometry and bioinformatics for biomarker discovery, and offers clinical trial support services across Europe. While its primary focus is on diagnostic products like therascreen® PITX2 and ELAEXIA® FITC, Therawis also provides extensive medical affairs and clinical operations services to pharmaceutical partners, positioning itself at the intersection of diagnostics and therapeutic development.
View full company profile